- Barclays reaffirmed its ‘Overweight’ rating on the LLY stock and its $1,350 price target on Tuesday, according to a TipRanks report.
- The brokerage recommended buying the stock ahead of a likely U.S. FDA approval of Lilly’s new weight-loss pill.
- Eli Lilly is expected to receive regulatory action on orforglipron, its oral weight-loss therapy, on April 10, 2026.
Eli Lilly (LLY) shares have been under downward pressure lately, heading for a fifth loss in six sessions as the stock tested its 200-day moving average for the first time since October 2025.
LLY stock was down 1% at the time of writing and has declined nearly 10% over the past six sessions.
Source: TradingView
Retail sentiment for LLY on Stocktwits turned ‘bearish’ from ‘bullish’ a day earlier.
Barclays Says Stock Too Cheap To Ignore
Barclays reaffirmed its “overweight” rating on the stock and the $1,350 price target on Tuesday, according to a report by TipRanks.
With shares down nearly 20% this year and trading near $900, Barclays analyst Emily Field says the stock is too cheap to ignore. She also noted that buying before the likely U.S. Food and Drug Administration (FDA) approval of Lilly’s new weight-loss pill could be a smart move.
Eli Lilly is expected to receive regulatory action on orforglipron, its oral weight-loss therapy, on April 10, 2026.
The brokerage began coverage of the stock last month, noting that the company is poised to maintain its lead in the obesity drug market and that its shares warrant a premium valuation.
Out of 31 analysts covering the stock, 24 have a “Buy” rating, six have “Hold,” and just one has “Sell,” according to Koyfin data. The average price target is $1,209.
Lilly’s Experimental Diabetes Drug Trial Shows Strong Results
Last week, Eli Lilly reported strong Phase 3 results for its experimental drug Retatrutide, aimed at patients with type 2 diabetes. The once-weekly injectable targets three hormone receptors—GLP-1, GIP, and glucagon—and showed significant benefits over placebo after 40 weeks.
Patients experienced A1C drops, a measure of blood sugar, of up to 2% and average weight loss of 36.6 pounds (17 kg). The results highlight Retatrutide’s potential in the growing obesity market, where injectables like Novo Nordisk’s Wegovy and Lilly’s own Zepbound currently lead. Analysts see Retatrutide’s sales possibly exceeding $10.6 billion by 2036.
Year-to-date, the stock has shed more than 16%.
Read also: IBRX Stock Plunges 27% After FDA Flags ‘Misleading’ Promotion Of Bladder Cancer Drug ANKTIVA
For updates and corrections, email newsroom[at]stocktwits[dot]com.